Transforming growth factor beta receptor type I and type II (TGF-βRI and TGF-βRII)

Transforming growth factor beta receptor type I and type II are transmembrane serine/threonine kinase receptors that mediate the cellular response to transforming growth factor beta (TGF-β) ligands[1][3][5]. Upon binding of TGF-β, the constitutively active type II receptor dimer recruits and phosphorylates the type I receptor dimer, enabling type I receptor kinase activity and initiation of downstream signaling primarily through SMAD transcription factors[6][7][8]. These receptors regulate diverse biological processes including cell growth, apoptosis, differentiation, tissue repair, and immune modulation. Dysregulation of TGF-β receptor signaling is implicated in a wide range of diseases, especially fibrosis, cancer, and autoimmune conditions. Targeted therapies against TGF-β receptors are under clinical investigation for their roles in modulating tumor microenvironment and reducing fibrotic disease progression, but clinical use requires careful monitoring due to the pleiotropic and essential roles of this pathway in normal physiology[1][3][7].

Other names

TGF-beta receptor type ITGF-beta receptor type IITβRI (also known as activin receptor-like kinase 5 or ALK5)TβRIITGFBR1TGFBR2TGF-β receptor I/IIType I/II TGF-β receptor

Inhibition of TGF-βRI kinase activity (small molecules) Blockade of TGF-β ligand binding (antibodies) Dual inhibition of TGF-βRI and TGF-βRII Disruption of receptor dimerization/complex formation